Literature DB >> 12524136

Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions.

Masahide Nakajima1, Kazutaka Hayashi, Ken-ichi Katayama, Yusaku Amano, Yasuhiro Egi, Masayoshi Uehata, Nobuharu Goto, Takao Kondo.   

Abstract

The signaling pathway of Rho and Rho-associated coiled-coil forming protein kinase (ROCK) is involved in tumor metastasis. In the present study, we investigated the suppressive effect of a novel inhibitor of ROCK, Wf-536 [(+)-(R)-4-(1-Aminoethyl)-N-(4-pyridyl) benzamide monohydrochloride], on spontaneous tumor metastasis in vivo and analyzed its action on tumor cell motility and angiogenesis to clarify its action mechanism. Wf-536 (0.3-3 mg/kg/day) was found to inhibit Lewis lung carcinoma (LLC) metastasis and LLC-induced angiogenesis in orally treated mice; in vitro, it inhibited both invasion and migration by LLC cells and invasion, migration, and formation of capillary-like tubes on Matrigel by endothelial cells, without cytotoxicity or anti-proliferative action in either cell type. We conclude that Wf-536 has tumor anti-metastatic activity which may depend on inhibition of tumor motility and angiogenesis. The findings support its further clinical development as an anti-metastatic agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524136     DOI: 10.1016/s0014-2999(02)02869-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events.

Authors:  Amanda P Struckhoff; Jason R Vitko; Manish K Rana; Carter T Davis; Kamau E Foderingham; Chi-Hsin Liu; Lyndsay Vanhoy-Rhodes; Steven Elliot; Yun Zhu; Matt Burow; Rebecca A Worthylake
Journal:  J Cell Sci       Date:  2010-01-05       Impact factor: 5.285

Review 2.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

Review 3.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

4.  Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).

Authors:  Roberta Pireddu; Kara D Forinash; Nan N Sun; Mathew P Martin; Shen-Shu Sung; Brian Alexander; Jin-Yi Zhu; Wayne C Guida; Ernst Schönbrunn; Saïd M Sebti; Nicholas J Lawrence
Journal:  Medchemcomm       Date:  2012-01-27       Impact factor: 3.597

5.  Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1.

Authors:  Kai-Chang Zhu; Jian-Mei Sun; Jian-Guo Shen; Ji-Zhong Jin; Feng Liu; Xiao-Lin Xu; Lin Chen; Lin-Tao Liu; Jia-Ju Lv
Journal:  Oncol Lett       Date:  2015-08-18       Impact factor: 2.967

Review 6.  Rho/ROCK signaling in motility and metastasis of gastric cancer.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

7.  ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.

Authors:  Akio Shimizu; Akiko Mammoto; Joseph E Italiano; Elke Pravda; Andrew C Dudley; Donald E Ingber; Michael Klagsbrun
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

8.  Crystal structure of a coiled-coil domain from human ROCK I.

Authors:  Daqi Tu; Yiqun Li; Hyun Kyu Song; Angela V Toms; Christopher J Gould; Scott B Ficarro; Jarrod A Marto; Bruce L Goode; Michael J Eck
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

Review 9.  Regulation of ROCK activity in cancer.

Authors:  Marie Morgan-Fisher; Ulla M Wewer; Atsuko Yoneda
Journal:  J Histochem Cytochem       Date:  2012-11-29       Impact factor: 2.479

10.  A synthetic, xeno-free peptide surface for expansion and directed differentiation of human induced pluripotent stem cells.

Authors:  Sha Jin; Huantong Yao; Jennifer L Weber; Zara K Melkoumian; Kaiming Ye
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.